Annovis Bio Inc
ANVS2.631USD
+0.121+4.83%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
51.27MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Annovis Bio Inc Unternehmen
Annovis Bio, Inc. is a clinical-stage drug platform company addressing neurodegeneration such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and other chronic neurodegenerative diseases. The Company is developing its lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. Its product candidate ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after traumatic brain injury (TBI) and/or stroke. ANVS405 is the same compound as Buntanetap, given in cases of acute head and brain trauma. ANVS301 is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia. ANVS301 is observed to improve memory and learning in very old rats by lowering the number of errors from six to three.
Unternehmensinformationen
BörsenkürzelANVS
Name des UnternehmensAnnovis Bio Inc
IPO-datumJan 29, 2020
CEODr. Maria L. Maccecchini, Ph.D.
Anzahl der mitarbeiter8
WertpapierartOrdinary Share
GeschäftsjahresendeJan 29
Addresse101 Lindenwood Drive, Suite 225
StadtMALVERN
BörseNYSE Consolidated
LandUnited States of America
Postleitzahl19355
Telefon14848753192
Websitehttps://www.annovisbio.com/
BörsenkürzelANVS
IPO-datumJan 29, 2020
CEODr. Maria L. Maccecchini, Ph.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Michael B. Hoffman
Mr. Michael B. Hoffman
Independent Chairman of the Board
Independent Chairman of the Board
1.67M
+1.52%
Mr. Andrew Walsh
Mr. Andrew Walsh
Vice President - Finance, Principal Financial Officer
Vice President - Finance, Principal Financial Officer
500.00
--
Dr. Maria L. Maccecchini, Ph.D.
Dr. Maria L. Maccecchini, Ph.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
--
--
Dr. Claudine E. Bruck, Ph.D.
Dr. Claudine E. Bruck, Ph.D.
Independent Director
Independent Director
--
--
Mr. Reid S. Mccarthy
Mr. Reid S. Mccarthy
Independent Director
Independent Director
--
--
Mr. Mark White
Mr. Mark White
Director, Chief Business Officer
Director, Chief Business Officer
--
--
Eve Damiano
Eve Damiano
Senior Vice President - Regulatory
Senior Vice President - Regulatory
--
--
,
,
Vice President - Process Chemistry
Vice President - Process Chemistry
--
--
Cheng Fang
Cheng Fang
Senior Vice President - Research and Development
Senior Vice President - Research and Development
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Michael B. Hoffman
Mr. Michael B. Hoffman
Independent Chairman of the Board
Independent Chairman of the Board
1.67M
+1.52%
Mr. Andrew Walsh
Mr. Andrew Walsh
Vice President - Finance, Principal Financial Officer
Vice President - Finance, Principal Financial Officer
500.00
--
Dr. Maria L. Maccecchini, Ph.D.
Dr. Maria L. Maccecchini, Ph.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
--
--
Dr. Claudine E. Bruck, Ph.D.
Dr. Claudine E. Bruck, Ph.D.
Independent Director
Independent Director
--
--
Mr. Reid S. Mccarthy
Mr. Reid S. Mccarthy
Independent Director
Independent Director
--
--
Mr. Mark White
Mr. Mark White
Director, Chief Business Officer
Director, Chief Business Officer
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, Jul 19
Aktualisiert: Sat, Jul 19
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Hoffman (Michael B)
8.57%
Maccecchini (Maria-Luisa)
5.72%
Heights Capital Management, Inc.
5.13%
The Vanguard Group, Inc.
3.33%
Two Sigma Investments, LP
1.33%
Other
75.93%
Aktionäre
Aktionäre
Anteil
Hoffman (Michael B)
8.57%
Maccecchini (Maria-Luisa)
5.72%
Heights Capital Management, Inc.
5.13%
The Vanguard Group, Inc.
3.33%
Two Sigma Investments, LP
1.33%
Other
75.93%
Aktionärstypen
Aktionäre
Anteil
Individual Investor
14.69%
Investment Advisor
11.83%
Investment Advisor/Hedge Fund
1.76%
Hedge Fund
1.75%
Research Firm
0.51%
Family Office
0.10%
Bank and Trust
0.05%
Pension Fund
0.03%
Other
69.28%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
103
5.97M
30.62%
-274.28K
2025Q1
104
5.95M
41.64%
-106.94K
2024Q4
93
4.41M
22.61%
-199.92K
2024Q3
85
4.03M
23.62%
-296.86K
2024Q2
80
3.84M
23.67%
-697.75K
2024Q1
77
3.92M
38.68%
-550.67K
2023Q4
77
3.92M
40.01%
-464.08K
2023Q3
81
3.83M
42.48%
-299.71K
2023Q2
104
3.90M
43.31%
-104.02K
2023Q1
106
3.34M
40.86%
-680.15K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Hoffman (Michael B)
1.67M
8.57%
+25.00K
+1.52%
Jun 13, 2025
Maccecchini (Maria-Luisa)
1.11M
5.72%
+46.00K
+4.31%
Jun 04, 2025
Heights Capital Management, Inc.
1.00M
5.13%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
647.92K
3.33%
+181.64K
+38.96%
Mar 31, 2025
Two Sigma Investments, LP
259.14K
1.33%
+248.22K
+2272.43%
Mar 31, 2025
UBS Financial Services, Inc.
160.88K
0.83%
+112.14K
+230.10%
Mar 31, 2025
Geode Capital Management, L.L.C.
152.61K
0.78%
+53.05K
+53.28%
Mar 31, 2025
Susquehanna International Group, LLP
127.70K
0.66%
+72.39K
+130.88%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
99.49K
0.51%
-1.29K
-1.28%
Mar 31, 2025
Consilium Associates
97.82K
0.5%
-700.00
-0.71%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
iShares Micro-Cap ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
iShares Micro-Cap ETF
Anteil0%
iShares Core S&P Total U.S. Stock Market ETF
Anteil0%
DFA Dimensional US Sustainability Core 1 ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
